A DARPin promotes faster onset of botulinum neurotoxin A1 action.

Autor: Leka O; Laboratory of Biomolecular Research, Division of Biology, Paul Scherrer Institut, 5232, Villigen PSI, Switzerland., Wu Y; Laboratory of Biomolecular Research, Division of Biology, Paul Scherrer Institut, 5232, Villigen PSI, Switzerland., Zanetti G; Department of Biomedical Sciences, University of Padova, 35121, Padova, Italy., Furler S; Department of Biochemistry, University of Zurich, 8057, Zurich, Switzerland., Reinberg T; Department of Biochemistry, University of Zurich, 8057, Zurich, Switzerland., Marinho J; Department of Biochemistry, University of Zurich, 8057, Zurich, Switzerland., Schaefer JV; Department of Biochemistry, University of Zurich, 8057, Zurich, Switzerland., Plückthun A; Department of Biochemistry, University of Zurich, 8057, Zurich, Switzerland., Li X; Laboratory of Biomolecular Research, Division of Biology, Paul Scherrer Institut, 5232, Villigen PSI, Switzerland., Pirazzini M; Department of Biomedical Sciences, University of Padova, 35121, Padova, Italy., Kammerer RA; Laboratory of Biomolecular Research, Division of Biology, Paul Scherrer Institut, 5232, Villigen PSI, Switzerland. Richard.Kammerer@psi.ch.

Publikováno v: Nature communications [Nat Commun] 2023 Dec 18; Vol. 14 (1), pp. 8317. Date of Electronic Publication: 2023 Dec 18.

Exceptionally potent human monoclonal antibodies are effective for prophylaxis and treatment of tetanus in mice.

Autor: Pirazzini M; Department of Biomedical Sciences, University of Padova, Padova, Italy., Grinzato A; Department of Biomedical Sciences, University of Padova, Padova, Italy., Corti D; Humabs BioMed SA, Bellinzona, Switzerland., Barbieri S; Humabs BioMed SA, Bellinzona, Switzerland., Leka O; Department of Biomedical Sciences, University of Padova, Padova, Italy., Vallese F; Department of Biomedical Sciences, University of Padova, Padova, Italy., Tonellato M; Department of Biomedical Sciences, University of Padova, Padova, Italy., Silacci-Fregni C; Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland., Piccoli L; Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland., Kandiah E; European Synchrotron Radiation Facility, Grenoble, France., Schiavo G; Department of Neuromuscular Diseases, Queen Square Institute of Neurology and.; UK Dementia Research Institute, University College London, London, United Kingdom., Zanotti G; Department of Biomedical Sciences, University of Padova, Padova, Italy., Lanzavecchia A; Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.; Fondazione Istituto Nazionale Genetica Molecolare, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy., Montecucco C; Department of Biomedical Sciences, University of Padova, Padova, Italy.; Institute of Neuroscience, National Research Council, Padova, Italy.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2021 Nov 15; Vol. 131 (22).

Crystal structure of the catalytic domain of botulinum neurotoxin subtype A3.

Autor: Leka O; The Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institute, Villigen PSI, Switzerland., Wu Y; The Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institute, Villigen PSI, Switzerland., Li X; The Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institute, Villigen PSI, Switzerland., Kammerer RA; The Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institute, Villigen PSI, Switzerland. Electronic address: richard.kammerer@psi.ch.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2021 Jan-Jun; Vol. 296, pp. 100684. Date of Electronic Publication: 2021 Apr 21.

Excitation-contraction coupling inhibitors potentiate the actions of botulinum neurotoxin type A at the neuromuscular junction.

Autor: Machicoane M; Fastox Pharma SA, Lausanne, Switzerland., Tonellato M; Department of Biomedical Sciences, University of Padova, Padova, Italy., Zainotto M; Department of Biomedical Sciences, University of Padova, Padova, Italy., Onillon P; Fastox Pharma SA, Lausanne, Switzerland., Stazi M; Department of Biomedical Sciences, University of Padova, Padova, Italy., Corso MD; Department of Biomedical Sciences, University of Padova, Padova, Italy., Megighian A; Department of Biomedical Sciences, University of Padova, Padova, Italy.; Padova Neuroscience Center, University of Padova, Padova, Italy., Rossetto O; Department of Biomedical Sciences, University of Padova, Padova, Italy.; Institute of Neuroscience, Italian Research Council, University of Padova, Padova, Italy.; Interdepartmental Research Center of Myology CIR-Myo, University of Padova, Padova, Italy., Le Doussal JM; Fastox Pharma SA, Lausanne, Switzerland., Pirazzini M; Department of Biomedical Sciences, University of Padova, Padova, Italy.; Interdepartmental Research Center of Myology CIR-Myo, University of Padova, Padova, Italy.

Publikováno v: British journal of pharmacology [Br J Pharmacol] 2024 Oct 10. Date of Electronic Publication: 2024 Oct 10.

Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications.

Autor: Rasetti-Escargueil, Christine¹ (AUTHOR) christine.rasetti-escargueil@icr.ac.uk, Palea, Stefano² (AUTHOR) stefano.palea@humana-biosciences.com

Publikováno v: Toxins. Jun2024, Vol. 16 Issue 6, p261. 29p.